If you have been reading about immunoassay and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Appearance | Lyophilized powder | White to off-white solid |
| Storage temperature | Approximately -20 °C | Dry, dark, desiccated |
| Solubility | Water-soluble peptide | Depends on sequence and buffer |
| Identity method | Mass spectrometry | Confirms expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main-peak proportion |
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Transamination is mediated by several types of aminotransferase enzymes. An aminotransferase may be specific for an individual amino acid, or it may be able to process any member of a group of similar ones, for example the branched-chain amino acids, which comprises valine, isoleucine, and leucine. The two common types of aminotransferases are alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
The third generation of the Familia Presto was announced in September 1973, a month before the 1973 oil crisis. It was basically an updated version of the 1970 Familia Presto, reintroduced with 60 mm wider bodywork and reworked front and rear designs. It was promoted and marketed as the "Widebody" in Japan. These changes were made only to the saloons and coupé, while the van/wagon and pickups remained in production and retaining the original narrower bodywork with minor changes. The Familia Presto continued using the "Mazda 1000/1300" name in most export markets, "Mazda Marella" name was also retained in Finland. The Rotary Presto saloon/coupé was discontinued in Japan, having been replaced by the larger Grand Familia-based Mazda Savannah. The piston-engined 1000/1300 and rotary-engined R100 coupés were also replaced by 808/818/RX-3 coupé for export market. This generation was not available in North America and replaced by the bigger 808/Mizer/RX-3. Developed to meet new stricter emissions standards in the domestic market, the Presto featured the 1272 cc TC engine or the by now familiar, pushrod 1.0-litre PB unit. Power outputs in Japan (JIS gross) are 62 PS (46 kW; 61 hp) and 87 PS (64 kW; 86 hp) respectively, 50 PS (37 kW; 49 hp) and 66 PS (49 kW; 65 hp) (DIN) for export markets. Production of the third generation Familia ended in January 1977, but not before another minor facelift and emissions scrubbing had taken place in February 1976. This changes were not applied for export market.
Nobel Prize in Physiology or Medicine (1929) Bernard Horecker (1914–2010). American biochemist at Cornell University known for elucidation of the pentose phosphate pathway. Member Natl. Acad. Sci. USA. Linda Hsieh-Wilson (PhD 1996). American chemist known for work in chemical neurobiology and the structure and function of carbohydrates in the nervous system Wayne L. Hubbell (b. 1943). American biochemist at UCLA, pioneer of site-directed spin labelling. Member Natl. Acad. Sci. USA. Hugh Huxley (1924–2013). British molecular biologist at University College London and Brandeis University noted for discovery the underlying principle of muscle movement.
Sources: en.wikipedia.org
== History == Protein rich in phosphate was discovered early on. In 1906, Levene and Alsberg studied cleavage products of yolk vitellin, and showed that a phosphorus-rich proteinaceous fraction could be obtained from it. In 1933, Fritz Lipmann detected phosphoserine in casein. In 1948, a particularly phosphate-rich protein was isolated from yolk, and it was named phosvitin. Phosphorylase enzymes were discovered later. The first phosphorylase enzyme was discovered by Carl and Gerty Cori in the late 1930s. Carl and Gerty Cori found two forms of glycogen phosphorylase which they named A and B but did not correctly understand the mechanism of the B form to A form conversion. In 1954, another enzyme was discovered, which transfers phosphate from ATP onto a protein. Its physiological function was still not known. Glycogen phosphorylation was better understood later. The interconversion of phosphorylase b to phosphorylase a was described by Edmond Fischer and Edwin Krebs involving a phosphorylation/dephosphorylation mechanism. It was found that an enzyme named phosphorylase kinase and Mg-ATP were required to phosphorylate glycogen phosphorylase by assisting in the transfer of the γ-phosphoryl group of ATP to a serine residue on phosphorylase b. Protein phosphatase 1 is able to catalyze the dephosphorylation of phosphorylated enzymes by removing the phosphate group. Sutherland and Coris discovered epinephrine acts by activating phosphorylase, which leads to the formation of glucose from glycogen.
=== Economic policy === Ford's government cancelled the basic income pilot project. He opposes the laying off of government workers. He supports the use of attrition to eliminate government jobs that he believes are not needed. Ford believes in hiring independent auditors to audit government spending. Jay Goldberg of the Canadian Taxpayers Federation labelled Ford's spending excessive and noted Ontario's large debt increases under his government. In June 2019, Rod Phillips, who served as Minister of the Environment, Conservation and Parks, replaced Vic Fedeli as Ontario's finance minister. Andrea Khanjin was appointed as Parliamentary Assistant to the Minister of the Environment, Conservation and Parks in June 2018. Starting in January 2019, those who are working full-time and earning less than $30,000 a year would pay no provincial income tax, in the new LIFT program but minimum wage would be frozen at $14 per hour. They eliminated 3 legislative offices including the Environmental Commissioner of Ontario (ECO), child and youth advocate and French language services commissioner positions. The surtax on the highest earning Ontarians that would have generated about $275 million in revenue, was cancelled. The proposed French language university was cancelled as were three university satellite campuses. Fedeli served as minister until he was moved to economic development in June 2019 in a major cabinet shuffle.
== Treatment == Recommendations to treat pressure ulcers include the use of bed rest, pressure redistributing support surfaces, nutritional support, repositioning, wound care (e.g., debridement, wound dressings) and biophysical agents (e.g., electrical stimulation). Reliable scientific evidence to support the use of many of these interventions, though, is lacking. More research is needed to assess how to best support the treatment of pressure ulcers, for example by repositioning.
The Fisher King (French: Roi Pêcheur) is a figure in the Arthurian legend, the last in a long line of British kings tasked with guarding the Holy Grail. The Fisher King is both the protector and physical embodiment of his lands, but a wound renders him impotent and his kingdom barren. Unable to walk or ride a horse, he is sometimes depicted as spending his time fishing while he awaits a hero who can heal him. Versions of the Grail King story vary widely, but the Fisher King, or the Maimed King (Roi Méhaigné), is typically depicted as being wounded in the groin, legs, or thigh. The healing of these wounds always depends upon the completion of a hero-knight's task. Besides the Holy Grail, the Lance of Longinus may feature as a key plot element. In some variants, a third character is introduced; this individual, unlike the hero-knight archetype, is ignorant of the King's power, but has the ability to save the king and land, or to doom it. As a literary character, the Fisher King originates in Chrétien de Troyes' unfinished writings of the adventures of the Grail Knight, Perceval. Many authors have endeavoured to complete and extend the work, resulting in various continuations. Major sources of the legend include Chrétien's Li Contes del Graal; Perceval, ou Le Conte du Graal (c. 1180–1190), Wauchier de Denain's First Continuation (c. 1190–1200), Robert de Boron's Didot-Perceval (c. 1191–1202), Peredur son of Efrawg (c. 1200), Perlesvaus (c. 1200), Wolfram von Eschenbach's Parzival (c. 1205), and Thomas Malory's Morte D'Arthur (c. 1400).
Sources: en.wikipedia.org
=== N- and C-termini === The peptides matched during protein identification do not necessarily include the N- or C-termini predicted for the matched protein. This may result from the N- or C-terminal peptides being difficult to identify by MS (e.g. being either too short or too long), being post-translationally modified (e.g. N-terminal acetylation) or genuinely differing from the prediction. Post-translational modifications or truncated termini may be identified by closer examination of the data (i.e. de novo sequencing). A repeat digest using a protease of different specificity may also be useful.
Such glare can lead to serious accidents and, in the case of pilots and truck drivers, to occupational disability due to eye damage. The first accident prevention regulation was published on April 1, 1988 as BGV B2, followed on January 1, 1997 by DGUV Regulation 11 of the German Social Accident Insurance. Between January and mid-September 2010, the German Federal Aviation Office registered 229 dazzle attacks on helicopters and airplanes of German airlines nationwide. On October 18, 2017, a perpetrator of a dazzle attack on a federal police helicopter was sentenced to one year and six months in prison without parole.
In 1958, HVEC established High Voltage Engineering Europa (HVEE) in Amersfoort, Netherlands to supply accelerators to the European common market. The subsidiary was created in response to demand for accelerators in the European common market and export-controlled markets. HVEE manufactured HVEC's lower-voltage Van de Graaff accelerators for industries in the European common market, as well as insulated-core transformer power supplies for low-voltage electron beams. According to production records compiled through 2004, HVEE manufactured 93 accelerators across various voltage ranges, mostly in the 0.5–2 MV range. HVEE also produced smaller numbers of higher-voltage systems, including three accelerators in the 5–7 MV range and one in the 4-5 MV range. High Voltage Engineering Europa continued operations after its parent company's bankruptcy. HVEE produced low-voltage 1–5 MV, solid-state voltage generators with the trade names Tandetron and Singletron, originally designed by the General Ionix Corporation in Massachusetts. Having shifted away from belt-charged accelerators, HVEE's lower voltage accelerators now incorporate newer charging technologies.
Sources: en.wikipedia.org
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.
Lower temperatures slow chemical degradation reactions such as hydrolysis and oxidation. Light and moisture protection addresses additional pathways that can alter the molecule during storage.
A purity figure describes the proportion of the detected signal attributed to the main peak under a specific method. Different methods can produce different values for the same sample.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.